Literature DB >> 19131046

The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.

Fabrizio Stocchi1.   

Abstract

The symptoms of Parkinson's disease can become increasingly difficult to control as the disease advances. Levodopa remains the most efficacious therapy for symptomatic treatment. However, with long-term therapy motor and non-motor complications develop. There is now accumulating evidence that several factors - the progressive pathology of Parkinson's disease, the change in drug pharmacodynamics, and the pulsatile manner in which short-acting dopaminergic agents stimulate striatal dopamine receptors - are key contributors to the priming of the basal ganglia for induction of motor complications. In this paper, an overview of the different factors inducing motor fluctuations and the role of dopamine receptors stimulation is provided.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19131046     DOI: 10.1016/S1353-8020(09)70005-7

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  9 in total

1.  Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.

Authors:  Matthias Löhle; Heinz Reichmann
Journal:  BMC Neurol       Date:  2011-09-22       Impact factor: 2.474

2.  A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias.

Authors:  Christopher A Lieu; Allen R Kunselman; Bala V Manyam; Kala Venkiteswaran; Thyagarajan Subramanian
Journal:  Parkinsonism Relat Disord       Date:  2010-05-31       Impact factor: 4.891

3.  L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.

Authors:  Jennifer M King; Gladson Muthian; Veronica Mackey; Marquitta Smith; Clivel Charlton
Journal:  Life Sci       Date:  2011-08-18       Impact factor: 5.037

4.  Non-Oral Drug Delivery in Parkinson's Disease: Current Applications and Future.

Authors:  Meliha Güneş; Sinem Yaprak Karavana
Journal:  Turk J Pharm Sci       Date:  2022-06-27

5.  Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.

Authors:  Dag Nyholm; Per Odin; Anders Johansson; Krai Chatamra; Charles Locke; Sandeep Dutta; Ahmed A Othman
Journal:  AAPS J       Date:  2012-12-11       Impact factor: 4.009

6.  Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.

Authors:  Hubert H Fernandez; Arvydas Vanagunas; Per Odin; Alberto J Espay; Robert A Hauser; David G Standaert; Krai Chatamra; Janet Benesh; Yili Pritchett; Steven L Hass; Robert A Lenz
Journal:  Parkinsonism Relat Disord       Date:  2013-01-01       Impact factor: 4.891

7.  Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease.

Authors:  Michael Epstein; David A Johnson; Robert Hawes; Nathan Schmulewitz; Arvydas D Vanagunas; E Roderich Gossen; Weining Z Robieson; Susan Eaton; Jordan Dubow; Krai Chatamra; Janet Benesh
Journal:  Clin Transl Gastroenterol       Date:  2016-03-31       Impact factor: 4.488

Review 8.  Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?

Authors:  Maria José Catalán; Angelo Antonini; Matilde Calopa; Ovidiu Băjenaru; Oriol de Fábregues; Adolfo Mínguez-Castellanos; Per Odin; José Manuel García-Moreno; Stephen W Pedersen; Zvezdan Pirtošek; Jaime Kulisevsky
Journal:  eNeurologicalSci       Date:  2017-07-02

9.  Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson's Disease: Clinical Trial Post Hoc Analyses.

Authors:  Rajesh Pahwa; Jason Aldred; Niodita Gupta; Emi Terasawa; Viviana Garcia-Horton; David R Steffen; Prasanna L Kandukuri; Vivek S Chaudhari; Yash J Jalundhwala; Yanjun Bao; Pavnit Kukreja; Stuart H Isaacson
Journal:  Neurol Ther       Date:  2022-02-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.